Hartford Investment Management Co. decreased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 5.1% in the 4th quarter, HoldingsChannel.com reports. The fund owned 5,785 shares of the medical equipment provider’s stock after selling 308 shares during the quarter. Hartford Investment Management Co.’s holdings in ABIOMED were worth $1,880,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. FMR LLC increased its holdings in ABIOMED by 34.2% in the second quarter. FMR LLC now owns 691,818 shares of the medical equipment provider’s stock valued at $282,988,000 after buying an additional 176,394 shares during the last quarter. Advisors Asset Management Inc. increased its holdings in ABIOMED by 15.6% in the second quarter. Advisors Asset Management Inc. now owns 20,774 shares of the medical equipment provider’s stock valued at $8,498,000 after buying an additional 2,809 shares during the last quarter. State of Alaska Department of Revenue increased its holdings in ABIOMED by 4.4% in the third quarter. State of Alaska Department of Revenue now owns 7,184 shares of the medical equipment provider’s stock valued at $3,230,000 after buying an additional 304 shares during the last quarter. NEXT Financial Group Inc acquired a new position in ABIOMED in the third quarter valued at $115,000. Finally, World Asset Management Inc boosted its stake in ABIOMED by 5.2% in the third quarter. World Asset Management Inc now owns 2,976 shares of the medical equipment provider’s stock valued at $1,338,000 after acquiring an additional 146 shares in the last quarter. Institutional investors own 95.25% of the company’s stock.

In other news, COO David M. Weber sold 24,000 shares of the stock in a transaction dated Friday, January 25th. The shares were sold at an average price of $351.47, for a total transaction of $8,435,280.00. Following the completion of the sale, the chief operating officer now owns 161,842 shares in the company, valued at $56,882,607.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Martin P. Sutter sold 5,985 shares of the stock in a transaction dated Wednesday, February 6th. The stock was sold at an average price of $349.49, for a total transaction of $2,091,697.65. Following the sale, the director now owns 212,943 shares of the company’s stock, valued at approximately $74,421,449.07. The disclosure for this sale can be found here. Insiders have sold 49,928 shares of company stock valued at $17,512,612 in the last quarter. Insiders own 3.50% of the company’s stock.

Several equities analysts have issued reports on ABMD shares. BTIG Research upgraded shares of ABIOMED from a “neutral” rating to a “buy” rating and set a $450.00 price objective for the company in a research note on Friday, November 2nd. Morgan Stanley upgraded shares of ABIOMED from an “equal” rating to a “weight” rating and upped their price objective for the company from $396.00 to $496.00 in a research note on Wednesday, November 7th. BidaskClub downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Thursday, November 15th. ValuEngine downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Tuesday, November 20th. Finally, Zacks Investment Research downgraded shares of ABIOMED from a “buy” rating to a “hold” rating in a research note on Monday, December 10th. Nine research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and a consensus price target of $413.71.

Shares of ABMD opened at $341.21 on Monday. ABIOMED, Inc. has a fifty-two week low of $219.13 and a fifty-two week high of $459.75. The stock has a market cap of $15.39 billion, a PE ratio of 139.27, a price-to-earnings-growth ratio of 3.41 and a beta of 0.38.

ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, January 31st. The medical equipment provider reported $0.97 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.03. ABIOMED had a net margin of 30.12% and a return on equity of 20.31%. The business had revenue of $200.56 million during the quarter, compared to the consensus estimate of $200.60 million. Research analysts expect that ABIOMED, Inc. will post 3.61 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.thecerbatgem.com/2019/02/11/hartford-investment-management-co-cuts-stake-in-abiomed-inc-abmd.html.

ABIOMED Company Profile

ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.

Featured Story: Outstanding Shares, Buying and Selling Stocks

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.